×
About 54,545 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  17,281 results

Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated...
https://doi.org/10.12659/AJCR.935584
The American Journal of Case Reports; Haider A, Gurjar H et. al.

Jun 26th, 2022 - BACKGROUND Necrotizing fasciitis is a life-threatening infection of the deep soft tissues that leads to progressive destruction of the fascia and subcutaneous fat. It typically spreads along the muscle fascia planes because of the relatively poor ...

Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
https://doi.org/10.1002/ijc.34192
International Journal of Cancer; Husby A, Wohlfahrt J et. al.

Jun 26th, 2022 - A woman's reproductive history is strongly associated with her risk of ovarian cancer. However, it is unclear how pregnancies of different duration impact a woman's ovarian cancer risk, and therefore, what part of a pregnancy explains the protecti...

Weakly supervised deep learning for prediction of treatment effectiveness on ovarian ca...
https://doi.org/10.1016/j.compmedimag.2022.102093
Computerized Medical Imaging and Graphics : the Official ... Wang CW, Chang CC et. al.

Jun 26th, 2022 - Despite the progress made during the last two decades in the surgery and chemotherapy of ovarian cancer, more than 70 % of advanced patients are with recurrent cancer and decease. Surgical debulking of tumors following chemotherapy is the conventi...

Expression pattern and prognostic potential of histamine receptors in epithelial ovaria...
https://doi.org/10.1007/s00432-022-04114-x 10.1200/JCO.2002.20.1.125 10.1016/j.ygyno.2005.07.123 10.1016/0304-3835(94)90348-4 10.2174/187152810792231869 10.1016/0304-3835(95)90153-1 10.2147/CMAR.S210004 10.1042/cs0870151 10.2307/2529872 10.1002/cncr.24149 10.1016/s0006-2952(02)00975-9 10.1002/bimj.200410135 10.1158/1541-7786.MCR-09-0261 10.1016/j.cell.2011.02.013 10.1101/cshperspect.a026781 10.1016/j.ygyno.2016.08.243 10.1124/jpet.102.046581 10.1021/cn200126p 10.1016/j.jss.2005.02.030 10.1002/ijc.11538 10.1038/emm.2007.32 10.4062/biomolther.2019.135 10.1016/S1470-2045(13)70006-8 10.1111/bph.14535 10.1111/j.1476-5381.2010.00961.x 10.1016/S0021-9258(18)51471-X 10.2147/IJWH.S197604 10.1056/NEJMoa1810858 10.3390/biom11081232 10.1124/mol.116.104752 10.1038/sj.bjp.0706440 10.2217/14796694.4.2.169 10.1038/nm.3394 10.1007/s12094-020-02545-x 10.25259/aujmsr_16_2019 10.3322/caac.21590 10.1186/1748-717X-5-8 10.2307/1422689 10.3322/caac.21660 10.1517/14728220903188438 10.1254/jphs.fp0040691 10.3322/caac.21456 10.1016/j.ygyno.2022.01.024 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 10.1038/s41401-020-00548-6
Journal of Cancer Research and Clinical Oncology; Kraus FBT, Topalov NE et. al.

Jun 26th, 2022 - Despite recent advances in the treatment of ovarian cancer (OC), long-term remissions remain scarce. For a targeted approach, prognostic markers are indispensable for predicting survival and treatment response. Given their association with multipl...

Diagnostic performance of ultrasound in assessing the extension of disease in advanced ...
https://doi.org/10.1016/j.ajog.2022.05.029
American Journal of Obstetrics and Gynecology; Moruzzi MC, Bolomini G et. al.

Jun 26th, 2022 - Surgical exploration remains the gold standard to evaluate the extension of disease and predict resectability. A laparoscopy-based scoring model was developed by Fagotti and colleagues in 2006 and updated in 2015, based on the intraoperative prese...

see more →

Guidelines  54 results

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below th...
https://doi.org/10.1111/1471-0528.16896
BJOG : an International Journal of Obstetrics and Gynaeco... Manchanda R, Gaba F et. al.

Oct 22nd, 2021 - This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them m...

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0007
Journal of the National Comprehensive Cancer Network : JN... Armstrong DK, Alvarez RD et. al.

Feb 6th, 2021 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have...

SEOM clinical guideline in ovarian cancer (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058000
Clinical & Translational Oncology : Official Publication ... Redondo A, Guerra E et. al.

Jan 31st, 2021 - Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatm...

Breastfeeding Challenges: ACOG Committee Opinion, Number 820.
https://doi.org/10.1097/AOG.0000000000004253
Obstetrics and Gynecology;

Jan 23rd, 2021 - Breastfeeding is associated with a decrease in a woman's risk of breast cancer, ovarian cancer, diabetes mellitus, and hypertensive heart disease. Breastfeeding initiation rates in the United States are increasing, and many women are aware of the ...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

see more →

Drugs  83 results see all →

Clinicaltrials.gov  1,876 results

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02769962

Jun 24th, 2022 - Background: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. Urothelial Carcinoma (UC)...

Precision-Based Genomics in Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT04706663

Jun 24th, 2022 - Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States with an estimated 191,930 new cases and 33,330 deaths in 2020. There has been progress in identifying established risk factor...

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
https://clinicaltrials.gov/ct2/show/NCT01851369

Jun 24th, 2022 - Background: -Base excision repair (BER) of DNA repair pathway has been implicated in resistance to both alkylating and antimetabolite chemotherapy. -TRC102 (methoxyamine HCl) acts through a novel mechanism to inhibit BER and has demonstrated the a...

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
https://clinicaltrials.gov/ct2/show/NCT00339495

Jun 24th, 2022 - The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Execu...

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
https://clinicaltrials.gov/ct2/show/NCT04954599

Jun 24th, 2022 - This study is a First in Human, early phase (I/IIa), 3 modules, 2 parts (A- dose escalation and B- cohort expansion), open-label, uncontrolled, multi-center, multiple dose, accelerated 3+3 dose escalation study. The study consist of 3 study module...

see more →

News  2,500 results

How to better identify and manage women with elevated breast cancer risk
https://www.mdedge.com/familymedicine/article/255370/womens-health/how-better-identify-and-manage-women-elevated-breast
MDedge Family Medicine; Sarina Schrager, MD, MS, Brenna Bomcamp, BS et. al.

Jun 13th, 2022 - Breast cancer is the most common invasive cancer in women in the United States; it is estimated that there will be 287,850 new cases of breast cancer in the United States during 2022 with 43,250 deaths. 1 Lives are extended and saved every day beca.

Which Malnutrition Criteria to Use in Gynecologic Cancers?
https://www.medscape.com/viewarticle/974995

Jun 3rd, 2022 - Women with gynecologic cancers who meet criteria for malnutrition before surgery face a higher risk for poor postoperative outcomes. However, the value of preoperative malnutrition assessments depends on the definition of malnutrition used as well...

The perils of CA-125 as a diagnostic tool in patients with adnexal masses
https://www.mdedge.com/obgyn/article/254874/gynecologic-cancer/perils-ca-125-diagnostic-tool-patients-adnexal-masses
Katherine Tucker, MD

May 24th, 2022 - CA-125, or cancer antigen 125, is an epitope (antigen) on the transmembrane glycoprotein MUC16, or mucin 16. This protein is expressed on the surface of tissue derived from embryonic coelomic and Müllerian epithelium including the reproductive tra.

Serum pepsinogen is associated with gastric cancer risk
https://www.mdedge.com/hematology-oncology/article/254816/gastrointestinal-cancer/serum-pepsinogen-associated-gastric

May 23rd, 2022 - Key clinical point: Baseline serum pepsinogen levels are associated with a significant risk for gastric cancer, particularly the noncardia type. Major finding: A higher proportion of patients with gastric cancer vs matched controls had a positive.

Gynecologic Cancer Studies: What to Look for at ASCO 2022
https://www.medscape.com/viewarticle/973898

May 20th, 2022 - This transcript has been edited for clarity. I'm Maurie Markman from Cancer Treatment Centers of America. I would like to briefly comment on the abstracts that have been released for the American Society of Clinical Oncology (ASCO) meeting coming ...

see more →

Patient Education  24 results see all →